Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib

Christine M. Walko,Ronald E. Aubert,Ninh M. La-Beck,Gosia Clore,V. Herrera,Helen Kourlas,Robert S. Epstein,Howard L. McLeod

Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib

2017

Christine M. Walko
Ronald E. Aubert
Ninh M. La-Beck
Gosia Clore
V. Herrera
Helen Kourlas
Robert S. Epstein
Howard L. McLeod

Background. Thyroid dysfunction and hypertension (HTN) have been sporadically reported with sunitinib (SUN) and sorafenib (SOR). Determination of the side effect incidence will enhance monitoring and management recommendations.

Keywords:

Pharmacology
Sorafenib
Pharmacoepidemiology
Sunitinib
Medicine
Proportional hazards model
Cohort study
Hazard ratio
Clinical trial
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations